Israel Englander’s Aldeyra Therapeutics ALDX Stock Holding History

Israel Englander’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,200	Closed	-$111K	–	5972
2025 Q3	$111K	Buy	+21,200	New	+$111K	﹤0.01%	5683
2025 Q2	–	Sell	-41,300	Closed	-$237K	–	5824
2025 Q1	$237K	Buy	+41,300	New	+$244K	﹤0.01%	5214
2021 Q1	–	Sell	-200,000	Closed	-$1.37M	–	5857
2020 Q4	$1.37M	Buy	+200,000	New	+$1.4M	﹤0.01%	3513

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Israel Englander's ALDX Position: Q2 2026 in Review

Israel Englander reduced its Aldeyra Therapeutics (ALDX) stake by 64% in Q2 2026, selling an estimated $1.09M and leaving 360,350 shares worth $768K. The position accounts for ﹤0.01% of the portfolio, ranked #4500.

Israel Englander first reported a position in ALDX in Q2 2015 and has held it in 44 quarters since. The position peaked at $13.1M in Q3 2018. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Israel Englander held 360,350 shares of Aldeyra Therapeutics worth $768K as of Q2 2026.
Israel Englander sold 634,893 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.09M.
Aldeyra Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4500 holding.
Israel Englander first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 44 quarters since.
Israel Englander's Aldeyra Therapeutics position peaked at $13.1M in Q3 2018.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.